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Objectives: Vascular calciﬁcation has been associated inconsistently to low bone mineral density and
fractures. The aims of the present study were to investigate the associations between coronary artery
calciﬁcation (CAC) and BMD change, BMD and fracture risk in elderly subjects of the population-based
Rotterdam Study.
Methods: BMD was assessed through dual-energy X-ray absorptiometry and CAC through Electron-Beam
Computed Tomography in 582 men and 694 women. We investigated the associations between BMD
change (6.4 years follow-up) and CAC at follow-up and between BMD and CAC (measured simulta-
neously). In sensitivity analyses we stratiﬁed analyses for estradiol levels in women. The association
between CAC and fracture risk (9 years follow-up) was tested through competing-risks models. Models
were sex-stratiﬁed and adjusted for age, body mass index, smoking, bisphosphonate use and age at
menopause.
Results: There was no association between BMD change and CAC in men. In women, each 1% increase in
annual BMD loss was signiﬁcantly associated with higher follow-up CAC [b ¼ 0.22 (0.06e0.38),
p¼ 0.006; prevalence ratio: 4%]. Stratiﬁed analyses showed signiﬁcant associations between BMD loss
and follow-up CAC only in womenwith lower estradiol levels. We found no association between CAC and
fracture risk and no association between BMD and CAC cross-sectionally.
Conclusions: BMD loss was associated with higher follow-up CAC in women, which might be related to
low estrogen levels. No association between CAC and BMD or fracture risk was found. Further studies are
required to elucidate the mechanisms that might underlie the association between BMD change and
coronary calciﬁcation in women.
© 2015 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Osteoporosis and cardiovascular disease (CVD) are common
age-related diseases that have an increased co-existence indepen-
dent of shared risk factors such as increased age, menopause,
physical inactivity, alcohol intake and vitamin D deﬁciency [1].
Common pathophysiological mechanisms have been proposed
such as inﬂammatory cytokines, oxidized lipids, increased homo-
cysteine levels and decreased estrogen levels [1].terdam, The Netherlands.
Zillikens).
rved.Vascular calciﬁcation is deﬁned as the abnormal deposition of
calcium in the vascular system [2]. Formerly considered a passive
consequence of atherosclerosis, it is nowadays recognized as a
highly active process associated with an increased risk of cardio-
vascular events independently of other traditional risk factors [3].
The resemblance that ectopic calciﬁcation shares with the normal
calciﬁcation process of bone is remarkable and several studies [4,5]
have veriﬁed the observation made by Virchow in 1863 that
cardiovascular calciﬁcation is “an ossiﬁcation, not a mere calciﬁ-
cation” [6].
The increased co-existence of vascular calciﬁcation with osteo-
porosis [7] is called the calciﬁcation paradox. It has motivated
several investigators to evaluate whether bone mineral density
(BMD) and vascular calciﬁcation (VC) in several vascular beds are
Fig. 1. Flowchart for time line, design and sample size for the analyses.
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confounders [8e14]. Among studies with a cross-sectional design,
an inverse relation between aortic or coronary artery calciﬁcation
(CAC) and BMD has been reported by some [8,9] but not others
[10,11]. In contrast, longitudinal studies have consistently shown
that increased BMD loss is associated with increased aortic vascular
calciﬁcation assessed through different imaging modalities, such as
X-rays and radiogrammetry [12,13] as well as through computed
tomography [14], this relation has not been explained by aging and
other shared risk factors and has been found mainly in women.
Longitudinal studies evaluating the association between bone
turnover and CAC have been performed mainly in subjects with
chronic kidney disease, and results have been inconsistent;
while some studies have shown that low bone turnover is associ-
ated with increased risk of CAC [15] others have not replicated such
ﬁndings [16].
Studies addressing the association between vascular calciﬁca-
tion and fracture risk have focused mainly on aortic calciﬁcation,
and the results have been conﬂicting. While some of them
have reported an increased fracture risk with increased vascular
calciﬁcation [14,17], other studies have not found such results
[11,18].
Since previous studies found an association in women between
BMD loss and aortic vascular calciﬁcation we aimed to investigate
whether in the prospective population based Rotterdam study
changes in BMD are associatedwith vascular calciﬁcationmeasured
in the coronary arteries (CAC) in either sex and whether CAC is
associated with incidental fractures and BMD. We also studied
whether ﬁndings can be explained by hormonal status or bone
turnover.
2. Materials and methods
2.1. Study population
The Rotterdam Study is a prospective cohort study of elderly
men and women designed to investigate the incidence and de-
terminants of chronic disabling diseases. Rationale and design have
been described elsewhere [19]. The Rotterdam Study I cohort (RS-I)
was initiated in 1990 and consisted of 7983 participants. All sub-
jects were >55 years at recruitment and reside in Ommoord, a
district in Rotterdam and they have been assessed at baseline and
through four follow-up visits. BMD was measured in all follow-up
evaluations of the participants, and CAC scores were measured at
RS-I-3 visit (third evaluation of the RS-I cohort). In total, 1276
subjects had available information on CAC levels, previous BMD
measurements and incident fracture data (Fig. 1). The Rotterdam
Study was approved by the Medical Ethics Committee of Erasmus
MC.
2.2. DXA scanning
BMD was assessed using dual-energy X-ray absorptiometry
(DXA). Trained radiographic technicians performed BMD mea-
surements for participants at the ﬁrst visit (1990e1993) and the
third visit (1997e1999) with a GE Lunar DPX-L densitometer. For
the longitudinal analysis of BMD change and its association with
follow-up CAC, absolute annual percent BMD change at the femoral
neckwas calculatedwith the formula [100*(BMDRS-I-1 BMDRS-I-3)/
(BMDRS-I-1)*time length between measurements] [20], with a
positive value reﬂecting BMD loss. Results are expressed per 1%
increase in annual femoral neck BMD loss. Femoral neck BMD (from
henceforth referred to simply as BMD) was chosen, as it is not
affected by degenerative changes seen with age as lumbar spine
BMD and has been proposed for deﬁning osteoporosis inepidemiologic studies [21]. For the cross-sectional analyses of BMD
and CAC, BMD is expressed in sex-speciﬁc standard deviations (SD).
2.3. Coronary artery calciﬁcation assessment
At the third visit of the Rotterdam Study all participants who
completed the third phase of the Rotterdam Study were invited to
participate in the Rotterdam Coronary Calciﬁcation Study [22].
Epicardial coronary arteries calciﬁcation was detected by electron-
beam Computed Tomography (EBT; C-150 Imatron Scanner, GE
Healthcase, South San Francisco, CA). Before the subjects were
scanned, they performed adequate breath-holding exercises. From
the level of the root of the aorta through the heart, 38 images were
obtained with a 100-ms scan time and a 3-mm slice thickness.
During one breath hold, images were acquired at 80% of the cardiac
cycle by using echocardiographic triggering. Quantiﬁcation of cor-
onary calciﬁcation was performed with AccuImage software
(AccuImage Diagnostics Corporation, South San Francisco, CA)
displaying all pixels with a density >130 Hounsﬁeld Units (HU). The
presence of calciﬁcation was deﬁned as a minimum of 2 adjacent
pixels (area¼ 0.65 mm2) with a density >130 HU. Calcium scores
were calculated by multiplying the area in mm2 of individual
calciﬁed lesions with a factor based on the peak density of the
lesion. The total calciﬁcation score for the entire epicardial coronary
vascular system comprised the sum of the scores for all individual
lesions.
2.4. Fracture assessment
Fracture events were obtained from computerized records of
general practitioners (GPs) in the research area (covering 80% of the
cohort); additionally research physicians regularly followed
participant information in the GP's records outside the research
area. All reported events were veriﬁed by two trained research
physicians, who independently reviewed and coded the informa-
tion. Finally, all coded events were reviewed by amedical expert for
ﬁnal classiﬁcation according to the International Classiﬁcation of
Diseases, tenth revision (ICD-10) [23]. Participants were followed
from the date of the CAC scan until January 1, 2007, or until a ﬁrst
fracture or death occurred.
Table 1
General characteristics of the study population of 1276 men and women with in-
formation available on both BMD change and CAC.
Men (n¼ 582) Women (n¼ 694)
Visit 1 Visit 3 Visit 1 Visit 3
Age (y)a 64.1
(59.9e68.2)
70.5
(66.4e74.9)
63.7
(59.8e68.2)
70.2
(66.3e74.7)
BMI (kg/m2)a 25.9
(24.2e27.9)
26.2
(24.4e28.4)
25.9
(23.6e29.0)
26.8
(24.1e30.0)
BMD (g/cm2)b 0.93 (0.13) 0.91 (0.13) 0.86 (0.13) 0.81 (0.13)
Annual FN
BMD change
(%)a
e 0.37
(0.18e0.86)
e 0.78
(0.22e1.37)
Prevalent CAC (%) n/a 569 (98%) n/a 591 (85%)
CAC scorea n/a 271.5
(58.3e925.8)
n/a 48.7
(4.4e289.8)
Age at
menopausea (y)
n/a n/a 50.0 (46e52)
Smoking (%)c 544 (93%) 535 (92%) 372 (54%) 369 (53%)
Prevalent CV
diseased (%)
121 (21%) e 94 (13%) e
a Median and interquantile range.
b Mean and standard deviation.
c Current and former smokers.
d Prevalent cardiovascular disease, deﬁned as prevalent myocardial infarction,
heart failure or peripheral artery disease.
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Several covariates known to inﬂuence both BMD and coronary
artery calciﬁcation scores (CACs) [4,24e26] were included in the
regression models, particularly age, smoking, body mass index
(BMI) andmedication use (missingness <2%). BMI was calculated in
kg/m2, from height and weight measured in standing position
without shoes. BMI change was calculated as the absolute differ-
ence between measurements in the ﬁrst and third visit of the
Rotterdam Study. Smoking status was assessed by interview and
coded as never-, former- and current smokers. Cigarette pack-years
(for former and current smokers) were calculated as duration of
smoking (in years) multiplied by the number of smoked cigarettes,
divided by 20. Regarding medication use information, more than
99% of participants collected their drug prescriptions at seven
regional pharmacies, which are fully computerized. Complete drug
use information is available as of January 1st, 1991. The pharmacy
data include the Anatomical Therapeutical Chemical (ATC) code
from the World Health Organization (WHO) Collaboration Centre
for Drug Statistics Methodology, the collection dates, total amount
of drug units and product names of the drugs. Adjustments in our
analyses were done for bisphosphonate [2] and hormone replace-
ment therapy (HRT) use [27] due to the fact that both medication
types have potential beneﬁcial effects on vascular calciﬁcation.
Bisphosphonate use was deﬁned as exposure to the antiresorptive
medication of at least 365 cumulative days before the date of the
CAC scan. Further adjustments were done for serum lipid reducing
therapy (mainly statins) and diuretic use, due to its effects on BMD
and potential inﬂuence in coronary artery calciﬁcation [28].
Baseline comorbidity status was included in several models,
namely prevalent diabetes mellitus, heart failure, peripheral artery
disease andmyocardial infarction; deﬁnition of such cases has been
previously described elsewhere [29e32].
Laboratory covariates included in the analyses were 17b-estra-
diol (pmol/L) and alkaline phosphatase (missingness of 78% and
21%, respectively). For these measurements, non-fasting blood
samples were drawn by venipuncture at the baseline visit between
0830 and 16 h. Platelets were removed by centrifugation and
samples were stored at 80 C until measurements. 17b-estradiol
(E2) was measured by direct immunoassay, and alkaline phos-
phatase (AP) was measured through an enzymatic colorimetric
method. Other covariates included for further adjustments were
total cholesterol, creatinine, 25-hydroxyvitamin D, serum calcium
and phosphate levels, measured from blood samples obtained at
baseline as previously described [19]. Intake of dietary calcium and
Vitamin D was assessed by interview at baseline for food intake
assessment using an extensive semi quantitative food frequency
questionnaire (FFQ) at the study center by a trained dietician [19].
Additionally, analyses done for women were adjusted for age at
menopause, collected by interview in the ﬁrst visit.
2.6. Statistical analysis
Due to high skewness of the CAC measurements distribution
that could not be completely corrected after log transformation, the
association between BMD or BMD change and CAC scores was
tested through generalized linear models, allowing Gaussian but
also non-normal distributions for continuous variables. Log-
transformed CAC scores (Ln(CACþ 1)) were set as the dependent
variable, with either BMD or BMD change as independent variables,
adjusted for potential confounders. Fitness of different models was
compared through the Akaike Information Criteria e AIC [33],
models with lower values corresponding to a better ﬁt. For
assessment of the CAC score status in a binary fashion (yes/no),
prevalence ratios were obtained with a log link instead of logit link,due to the fact that odds ratios overestimate the relative risks when
the outcome is highly prevalent [34]. Assessments were made for
BMD change and prevalent CAC at the third visit of the Rotterdam
Study, between CAC and subsequent fractures, and cross-
sectionally for BMD and prevalent CAC both measured during the
third visit (see Fig. 1).
As part of sensitivity analyses, we tested the signiﬁcance of the
interaction terms between BMD change with 17b-estradiol and
alkaline phosphatase levels in those subsets with these measure-
ments available (n¼ 161 and n¼ 556 with 17b-estradiol and alka-
line phosphatase levels available, respectively) and performed
stratiﬁed analysis according to 17b-estradiol (pmol/L) and alkaline
phosphatase (U/L) levels, setting the cut-off point at the median
value. Furthermore, analyses were performed after exclusion of
participants with prevalent cardiovascular disease.
The association between CAC scores (at third visit) and incident
fractures during follow-up was tested using competing-risks
regression models which yield hazard ratio estimates and allow for
informative censoring [35]. In this setting, the outcome of a fracture
might not be seen because death occurs ﬁrst, mainly because
important risk factors for fracture incidence are shared for all-cause
mortality [36]. For this analysis, the beginning of the follow-up
period was set as the date of the CAC scan. The proportionality
assumption was tested building interaction terms with time.
Analyses were performed with subjects with complete infor-
mation on covariates, exposure and outcome.
SPSS (version 21.0, Armonk, NY: IBM Corp) and Stata (version 12,
College Station TX: Stata Corp LP) were used for analyses. Statistical
signiﬁcance was deﬁned as p< 0.05.
3. Results
General characteristics of the population with information
available on BMD change and CAC are displayed in Table 1. Age and
BMI were similar between men and women. Men had higher BMD,
lower BMD loss rate, heavier smoking habits, and almost six-times
higher CAC scores than women. CAC prevalence was high in both
men and women (more than 85%).
The association between BMD change at the femoral neck (be-
tween baseline and third visit over an average of 6.4 y period) and
Table 3
Risk of incidence of all types of fracture as a function of CAC scores at RS-I-3 (third
visit).
Model I Model II
no. of fxs HR (95% CI)a p no. of fxs HR (95% CI)a p
All-fracture incidence
Men 83/808 1.01 (0.90e1.14) 0.80 64/615 0.96 (0.86e1.08) 0.48
Women 171/872 1.02 (0.95e1.10) 0.48 124/655 0.99 (0.91e1.07) 0.75
Hazard ratios derived from competing-risks regression models.
Model I. Adjusted for age, BMI and smoking at RS-I-3.
Model II. Adjusted for covariates in Model Iþ BMD at RS-I-3.
a Hazard ratios expressed per increase in log CAC.
N. Campos-Obando et al. / Atherosclerosis 241 (2015) 278e283 281follow-up CAC is depicted in Table 2. We found no signiﬁcant asso-
ciations in men [b¼0.02 (95%CI: 0.20e0.17), p¼ 0.85); CAC
prevalence ratio of 1%, p¼ 0.16]. In women, we found that each 1%
increase in annual BMD losswas signiﬁcantly associatedwith higher
CAC score on follow-up [b ¼ 0.22 (0.06e0.38), p¼ 0.006] and with
higher CAC prevalence ratio of 4% (p¼ 0.007). Adjustment for
bisphosphonate use (n¼ 48 users among a total of 1276 analyzed
subjects) did not essentially change results. Additionally, adjust-
ments for prevalent diabetes mellitus status, lipid lowering therapy
(mainly statins) use, diuretic use, and levels of 25 hydroxyvitaminD,
calcium, phosphate, creatinine and total cholesterol and dietary
intake of calcium and vitamin D at baseline yielded similar results
(data not shown). These “full-model” analyses were performed in a
smaller subset of participants with available information in all
mentioned covariates (n¼ 235 men and n¼ 290 women).
We investigated a potential relation between CAC scores and
any type of fracture (total number of events¼ 254; Table 3). We
found no associations for any type of fracture incidence in either
sex (Table 3).
We performed a cross-sectional analysis of BMD and CAC scores
at the third visit (see Fig. 1), and found no association for either sex
(men: b¼0.03 (0.20e0.13), p¼ 0.68; women: b ¼ 0.01
(0.16e0.19), p¼ 0.89). Likewise, BMDwas not associatedwith CAC
prevalence in either sex in this cross-sectional analysis
(Supplementary Table 1).3.1. Sensitivity analysis
To further explore the association between BMD loss and follow-
up CAC, we built interaction terms between BMD loss and two cat-
egories of 17b-estradiol (E2) and alkaline phosphatase (AP) strati-
ﬁed by themedian values (n¼ 161 and n¼ 556womenwith E2 and
AP measurements available, respectively). The p value results for
both interaction terms were suggestive (p¼ 0.13); therefore we
proceeded to stratify the analysis of BMD loss and CAC by median
level of E2 and AP. Table 4 shows that the associations between BMD
loss and CAC seems to be conﬁned to women with E2 levels below
the median [b ¼ 0.55 (0.08e1.03), p¼ 0.02] and to women with AP
levels above the median [b ¼ 0.36 (0.12e0.60), p¼ 0.003].
In addition, we investigated the inﬂuence of HRT use (n¼ 119
HRT users) and prevalent CVD (n¼ 96 women) on the relationship
between BMD change and follow-up CAC in women, and the re-
sults remained robust after these additional analyses (data not
shown).Table 2
Annual percent BMD change at femoral neck and CAC scores in RS-I-3.
Model I Model II
CAC as continuous variable
n b (95% CI)a p n b (95% CI)a p
Men 582 0.02 (0.20e0.17) 0.85 582 0.02 (0.21e0.17) 0.83
Women 694 0.22 (0.06e0.38) 0.006 694 0.23 (0.07e0.39) 0.005
CAC as binary variableb
n PR (95% CI)c p n PR (95% CI)c p
Men 582 1.01 (0.99e1.02) 0.16 582 1.01 (0.99e1.02) 0.16
Women 694 1.04 (1.01e1.07) 0.007 694 1.04 (1.01e1.07) 0.007
Statistically signiﬁcant results are highlighted in bold.
Model I: adjusted for age, BMI, delta BMI, smoking; in women also age at meno-
pause.
Model II: adjusted for covariates in Model Iþ bisphosphonate use before the date of
the scan.
a b from linear regression for log CAC scores for 1% annual increase in BMD loss
(100*[BMDRS-I-1  BMDRS-I-3]/[BMDRS-I-1]*time length between measurements).
b CAC binary refers to presence/absence of CAC. Present CAC is deﬁned as a CAC
score above 0.
c Prevalence ratio of CAC for 1% annual increase in BMD loss.4. Discussion
Overall we found that BMD loss (within an average period of 6.4
years follow-up) was signiﬁcantly associated with higher follow-up
CAC scores in women persisting after adjusting for multiple factors.
This relationship was not observed for men, and we found no as-
sociation of CAC scores with subsequent fractures in either sex.
Our results are in line with three previous longitudinal studies
that reported a signiﬁcant association between BMD loss and
vascular calciﬁcations in the aorta in women [12e14] but associa-
tions of BMD change with CAC have not been reported in the
general population to the best of our knowledge. We hereby
describe for the ﬁrst time an association with CAC in a general
population setting of elderly (aged over 55 years). The association
we found was not confounded by age, smoking, changes in BMI or
bisphosphonate treatment.
The fact that BMD loss was associated with CAC among women
only might suggest involvement of underlying hormonal factors as
potential mechanisms. Exploratory stratiﬁed analyses showed that
the association of BMD loss with CAC scores was observed in those
women with lower baseline estradiol suggesting that low E2 levels
could be involved in the development of both coronary calciﬁcation
and BMD loss.
We found a signiﬁcant association in the subgroup of women
with higher AP levels, which may reﬂect higher bone turnover
status induced by estradiol deﬁciency in the postmenopausal state
[37]. AP induces the degradation of pyrophosphate (Pi), that plays a
key role in ectopic calciﬁcation inhibition [38] that otherwise
would occur in most tissues due to the fact that collagen, ubiqui-
tously present, acts as a potent nucleating agent for the deposition
of hydroxyapatite crystals [39]. The increased AP levels in the
postmenopausal state [40] may lead to lower Pi levels and therefore
loss of inhibition of vascular calciﬁcation.
Vascular Smooth Muscle Cells (VSMC) can undergo differentia-
tion towards an “osteoblast-like” phenotype, changing from aTable 4
Annual percent BMD change at femoral neck and CAC scores in RS-I-3 (third visit) in
women stratiﬁed by baseline 17b-estradiol (E2) and alkaline phosphatase (AP)
levels.
n b (95% CI)a p n b (95% CI)a p
E2> 16.4 pmol/Lb E2< 16.4 pmol/Lb
Women 81 0.03 (0.49e0.42) 0.88 80 0.55 (0.08e1.03) 0.02
AP< 76 U/Lc AP> 76 U/Lc
Women 278 0.06 (0.22e0.34) 0.68 278 0.36 (0.12e0.60) 0.003
Models adjusted for age, BMI, delta BMI, and smoking.
a b from linear regression for log CAC scores for 1% annual increase in BMD loss
(100*[BMDRS-I-1  BMDRS-I-3]/[BMDRS-I-1]*time length between measurements).
b E2 corresponds to baseline 17b-estradiol levels. Cut-off point was set at median
value.
c AP corresponds to baseline alkaline phosphatase levels. Cut-off point was set at
median value.
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extracellular matrix that eventually gets calciﬁed [4,41]. There are
several pathophysiological mechanisms that could explain the role
that E2 plays in vascular calciﬁcation inhibition. In the ﬁrst place, E2
prevents atherosclerotic plaque development [42], the only type of
lesion that can get calciﬁed in the coronary arteries as
M€onckeberg's medial calciﬁcation does not occur in this vascular
bed [43]. It has been previously shown that the administration of E2
decreases VSMC proliferation in animal and human models,
through activation of nitric oxide synthase [44] and through
decreased mitogen-induced VSMC proliferation. In second place,
VSMC and endothelial cells express RANK, RANKL and OPG, and
therefore can respond to RANKL stimulation. RANKL induces VC
through an increase in bone morphogenetic protein 2 (BMP-2, the
main stimuli of AP) and a decrease in matrix Gla protein (MGP), an
inhibitor of VC. Importantly, E2 is able to attenuate RANKL-induced
VC [42]. Therefore, through differential actions in the expression of
key proteins, E2 preserves the original contractile VSMC features,
decreasing trans-differentiation towards a calcifying phenotype
[44].
The beneﬁcial effects of E2 on the coronary bed have been re-
ported only in women [45]. This observation may explain the
absence of a signiﬁcant association between BMD loss and CAC in
men in our study, despite the fact that BMD loss in the aging men is
also associated with estradiol deﬁciency [46]. Consistent with our
results, Kiel and colleagues previously described a lack of associa-
tion between BMD loss and aortic calciﬁcation in men from the
Framingham cohort [12].
We observed no different association between BMD loss and
CAC regarding previous HRT use, suggesting that perhaps exoge-
nous estradiol administration did not counterbalance the loss of
atheroprotective effects associated with menopausal-related
endogenous 17b-estradiol decrease. However, it should be
emphasized that the age of HRT initiation or its duration in women
from our cohort might not have been appropriate or long enough
respectively to achieve a protective effect against coronary calciﬁ-
cation, as the majority of HRT users reported a treatment length of
less than 5 years and a previous RCT showed a beneﬁcial effect of
HRT after an average of 8.7 years of treatment in women aged
50e59 y at enrollment [27]. Nevertheless, it is important to
mention that the effects of estrogen in the vascular system are
complex and robust evidence has proven that in general HRT lacks
sufﬁcient beneﬁcial effects on cardiovascular disease in both pri-
mary and secondary prevention settings in postmenopausal
women [47].
Similar to other prospective studies performed in aortic calci-
ﬁcation [11,18], we found no signiﬁcant association between CAC
and all-fracture risk in either sex during a mean follow-up of 9
years. This analysis takes risk of death into account. Of note, sig-
niﬁcant associations between aortic calciﬁcation and fractures have
been previously [17] reported in studies with cross-sectional de-
signs or with utilization of odds ratios as estimates of relative risks
precluding determination of causality for the calciﬁcation process
on fracture risk. Furthermore, different devices in assessing bone
mineral density, diversity in covariates adjusted for or different
cohort characteristics might limit the comparability of results from
multiple studies. We used electron-beam CT, which is a high sen-
sible device to identify calciﬁcation and is superior to ﬂuoroscopic
measures; this is one of the strengths of our study.
Further strengths of our study include the prospective design in
BMD change and fracture assessment with high completeness of
follow-up [48] (more than 95%) that allows a better determination
of how the natural history of disease might occur. The availability of
several important confounders aid to decrease the bias introduced
by risk factors that inﬂuence BMD loss and CAC. The assessment oflongitudinal measurements of BMD using the same device avoided
the need for calibration. The stratiﬁed analyses according to 17b-
estradiol, AP levels and HRT use provide a deeper insight into the
mechanisms and suggest that low estradiol levels may underlie
both BMD loss and higher CAC but since these results derive from
small subgroup analyses they require replication in larger (cohort)
studies. There are other limitations. The analyses were performed
in a subsample of the Rotterdam Study with available data on CAC
measurement. However, despite some minor differences, charac-
teristics of the responders to the Rotterdam Coronary Calciﬁcation
Study were highly similar to those of the nonresponders [22].
Another limitation of the study is the lack of availability of PTH and
FGF23 serum levels. Nevertheless, an association between long-
term exposure of high PTH and vascular calciﬁcation has been
demonstrated mainly in patients with renal dysfunction [49] and
FGF23 does not seem to induce vascular calciﬁcation [50]. Despite
multiple adjustments, residual confounding cannot be discarded.
The fact that the entire cohort is composed of European Caucasians
limits the generalizability of our ﬁndings to other populations or
ethnic groups. Besides, the relatively short follow-up time available
for the incidental fracture analysis might have limited our ability to
detect an association between CAC and fracture risk. Furthermore,
the stratiﬁed analysis according to E2 and AP levelswere performed
only in a small subset of women with such information available.
In conclusion, we found that BMD loss is signiﬁcantly associated
with higher CAC scores on follow-up in women only and we found
no association between CAC levels and subsequent fractures. Our
ﬁndings suggest that endogenous estradiol deﬁciency might un-
derlie both pathological processes and thus be a shared risk factor
for BMD loss and CAC but further studies are required to replicate
these ﬁndings. Further research is warranted to explain the
mechanisms that might underlie the association between BMD loss
and CAC in women.
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